Also known as ACE910 and Hemlibra.
First FVIIIa mimetic offering monthly, two‑week and weekly subcutaneous prophylaxis in a single‑use pre-filled pen; CHMP has issued a positive opinion for EU approval.
Phase 3b switch study shows denecimig well tolerated after direct switch from emicizumab; pen injector preferred and thrombin generation rose to normal without excess clotting.
Three researchers honoured for creating a bispecific antibody that mimics Factor VIII, enabling subcutaneous dosing and bleed prevention irrespective of inhibitors.
Interim FRONTIER4 data show consistent safety and efficacy of denecimig across weekly, biweekly and monthly dosing, with low injection-site reactions and high zero-bleed rates.
